Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted.

By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Downgrade Hims & Hers Health, Inc. to Hold as FDA scrutiny and Novo’s lawsuit threaten compounded GLP-1 revenue. Click for ...

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA ...

Stock Market Today: The Dow Jones index rose as Nvidia shined. Oracle soared and Cathie Wood bought a Warren Buffett stock.

Kyndryl’s chief financial officer, David Wyshner, departs the company amid a review of its accounting practices.

Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The S&P 500 has not ...

What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...

Check out the companies making headlines before the bell. Oracle — Shares rose 2% after the technology firm received an ...

Hims & Hers Health Inc (NYSE:HIMS) shares are falling Thursday morning after the company announced a proposed convertible senior notes offering. What Happened: Hims & Hers Health announced plans on ...

Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at UnitedHealth Group have attracted the attention of investors, but a smaller player ...